974: A Vaccine For Pancreatic Cancer Continues To Show Promise
Pancreatic cancer is notoriously difficult to treat, and about 90% of diagnosed patients die from the disease. A team at Memorial Sloan Kettering has been working to improve those outcomes by developing a new mRNA vaccine for pancreatic cancer.A few years ago, the team embarked on a small trial to test the vaccine’s safety. Sixteen patients with pancreatic cancer received it, and even though it was a small study, the results were promising: Half the participants had an immune response, and in those patients the cancer hadn’t relapsed after 18 months.This week, the team released a new study in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.